Luo Feijun, Brooks David G, Ye Hongtao, Hamoudi Rifat, Poulogiannis George, Patek Charles E, Winton Douglas J, Arends Mark J
Department of Pathology, Addenbrooke's Hospital, University of Cambridge, UK.
Int J Exp Pathol. 2009 Oct;90(5):558-74. doi: 10.1111/j.1365-2613.2009.00667.x.
Summary K-ras mutations are found in 40-50% of human colorectal adenomas and carcinomas, but their functional contribution remains incompletely understood. Here, we show that a conditional mutant K-ras mouse model (K-ras(Asp12)/Cre), with transient intestinal Cre activation by beta-Naphthoflavone (beta-NF) treatment, displayed transgene recombination and K-ras(Asp12) expression in the murine intestines, but developed few intestinal adenomas over 2 years. However, when crossed with Apc(Min/+) mice, the K-ras(Asp12)/Cre/Apc(Min/+) offspring showed acceleration of intestinal tumourigenesis with significantly changed average lifespan (P < 0.05) decreased to 18.4 +/- 5.4 weeks from 20.9 +/- 4.7 weeks (control Apc(Min/+) mice). The numbers of adenomas in the small intestine and large intestine were significantly (P < 0.01) increased by 1.5-fold and 5.7-fold, respectively, in K-ras(Asp12)/Cre/Apc(Min/+) mice compared with Apc(Min/+) mice, with the more marked increase in adenoma prevalence in the large intestine. To explore possible mechanisms for K-ras(Asp12) and Apc(Min) co-operation, the Mitogen-activated protein kinase (Mapk), Akt and Wnt signalling pathways, including selected target gene expression levels, were evaluated in normal large intestine and large intestinal tumours. K-ras(Asp12) increased activation of Mapk and Akt signalling pathway targets phospho-extracellular signal-regulated kinase (pErk) and pAkt, and increased relative expression levels of Wnt pathway targets vascular endothelial growth factor (VEGF), gastrin, cyclo-oxygenase 2 (Cox2) and T-cell lymphoma invasion and metastasis 1 (Tiam1) in K-ras(Asp12)/Cre/Apc(Min/+) adenomas compared with that of Apc(Min/+) adenomas, although other Wnt signalling pathway target genes such as Peroxisome proliferator-activated receptor delta (PPARd), matrix metalloproteinase 7 (MMP7), protein phosphatase 1 alpha (PP1A) and c-myc remained unchanged. In conclusion, intestinal expression of K-ras(Asp12) promotes mutant Apc-initiated intestinal adenoma formation in vivo more in the large intestine than the small intestine, with evidence of synergistic co-operation between mutant K-ras and Apc involving increased expression of some Wnt-pathway target genes.
在40%-50%的人类结肠腺瘤和癌中发现K-ras突变,但其功能作用仍未完全明确。在此,我们展示了一种条件性突变K-ras小鼠模型(K-ras(Asp12)/Cre),通过β-萘黄酮(β-NF)处理在小鼠肠道中短暂激活肠道Cre,该模型在小鼠肠道中表现出转基因重组和K-ras(Asp12)表达,但在2年多的时间里仅形成了少数肠道腺瘤。然而,当与Apc(Min/+)小鼠杂交时,K-ras(Asp12)/Cre/Apc(Min/+)后代的肠道肿瘤发生加速,平均寿命显著改变(P<0.05),从20.9±4.7周降至18.4±5.4周(对照Apc(Min/+)小鼠)。与Apc(Min/+)小鼠相比,K-ras(Asp12)/Cre/Apc(Min/+)小鼠小肠和大肠中的腺瘤数量分别显著增加(P<0.01),分别增加了1.5倍和5.7倍,大肠中腺瘤发生率的增加更为明显。为了探究K-ras(Asp12)与Apc(Min)协同作用的可能机制,在正常大肠和大肠肿瘤中评估了丝裂原活化蛋白激酶(Mapk)、Akt和Wnt信号通路,包括选定的靶基因表达水平。与Apc(Min/+)腺瘤相比,K-ras(Asp12)增加了Mapk和Akt信号通路靶标磷酸化细胞外信号调节激酶(pErk)和pAkt的激活,并增加了K-ras(Asp12)/Cre/Apc(Min/+)腺瘤中Wnt通路靶标血管内皮生长因子(VEGF)、胃泌素、环氧化酶2(Cox2)和T细胞淋巴瘤侵袭和转移1(Tiam1)的相对表达水平,尽管其他Wnt信号通路靶标基因如过氧化物酶体增殖物激活受体δ(PPARd)、基质金属蛋白酶7(MMP7)、蛋白磷酸酶1α(PP1A)和c-myc保持不变。总之,K-ras(Asp12)在肠道中的表达在体内促进了由突变Apc引发的肠道腺瘤形成,在大肠中比在小肠中更明显,有证据表明突变K-ras与Apc之间存在协同作用,涉及一些Wnt通路靶标基因表达增加。